Danaher Co. (NYSE:DHR) Shares Sold by Angeles Investment Advisors LLC

Angeles Investment Advisors LLC reduced its position in Danaher Co. (NYSE:DHR) by 7.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,202 shares of the conglomerate’s stock after selling 96 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Danaher were worth $300,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Tsfg LLC raised its stake in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Danaher during the second quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the second quarter worth approximately $25,000. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher during the fourth quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher during the first quarter worth approximately $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research analyst reports. TD Cowen increased their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. The Goldman Sachs Group increased their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research report on Friday, September 6th. Finally, Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Stock Up 0.7 %

Shares of NYSE:DHR opened at $276.06 on Tuesday. The stock’s 50-day moving average price is $265.25 and its two-hundred day moving average price is $256.67. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The firm has a market cap of $199.37 billion, a price-to-earnings ratio of 46.79, a PEG ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company earned $2.05 EPS. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. On average, research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 in the last three months. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.